Sulforaphane Inhibits Inflammatory Responses of Primary Human T-Cells by Increasing ROS and Depleting Glutathione
Liang J, Jahraus B, Balta E, Ziegler JD, Hübner K, Blank N, Niesler B, Wabnitz GH, Samstag Y
Frontiers in immunology · 59 citas
Etiquetas de revisión
Solo mecanismosDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Estudio in vitro o de mecanismos (clasificado por nuestro filtro de IA)
- Estudiado en
- Células o muestras de laboratorio
- Resultado principal
- Solo mecanismos
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Deutsche Forschungsgemeinschaft
- Subvenciones
- Deutsche Forschungsgemeinschaft (SA 393/3-4)
Según 1 financiador declarado y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2018-11-14 · Front Immunol · vol. 9 · pág. 2584
- Editorial
- Frontiers Media
- Citado
- 77 citas · más que el 94% de estudios similares · 3.4× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 63 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Genomics, phytochemicals, and oxidative stress · IL-33, ST2, and ILC Pathways · Psoriasis: Treatment and Pathogenesis
- Palabras clave
- Sulforaphane, Glutathione, Oxidative stress, Reactive oxygen species, Chemistry, Inflammation, RAR-related orphan receptor gamma, Transcription factor, T cell, Immune system, Antioxidant, Cell biology, Immunology, Pharmacology, Biochemistry, Biology, Enzyme
- MeSH
- t-lymphocytes, cells, cultured, humans, brassicaceae, arthritis, rheumatoid, inflammation, reactive oxygen species, isothiocyanates, sulfoxides, glutathione, anti-inflammatory agents, interleukins, interleukin-17, down-regulation, stat3 transcription factor, nuclear receptor subfamily 1, group f, member 3, primary cell culture, immunosuppression therapy, interleukin-22
9 autores
- Jie Liang🇩🇪Heidelberg University
- Beate Jahraus🇩🇪Heidelberg University
- Emre Balta🇩🇪Heidelberg University
- Jacqueline D. Ziegler🇩🇪Heidelberg University
- Katrin Hübner🇩🇪Heidelberg University
- Norbert Blank🇩🇪Heidelberg University
- Beate Niesler🇩🇪Heidelberg University
- Guido H. Wabnitz🇩🇪Heidelberg University
- Yvonne Samstag🇩🇪 · autor de correspondenciaHeidelberg University
Resumen
El texto original del estudio, en el idioma en que se publicó.
The activity and function of T-cells are influenced by the intra- and extracellular redox milieu. Oxidative stress induces hypo responsiveness of untransformed T-cells. Vice versa increased glutathione (GSH) levels or decreased levels of reactive oxygen species (ROS) prime T-cell metabolism for inflammation, e.g., in rheumatoid arthritis. Therefore, balancing the T-cell redox milieu may represent a promising new option for therapeutic immune modulation. Here we show that sulforaphane (SFN), a compound derived from plants of the Brassicaceae family, e.g., broccoli, induces a pro-oxidative state in untransformed human T-cells of healthy donors or RA patients. This manifested as an increase of intracellular ROS and a marked decrease of GSH. Consistently, increased global cysteine sulfenylation was detected. Importantly, a major target for SFN-mediated protein oxidation was STAT3, a transcription factor involved in the regulation of TH17-related genes. Accordingly, SFN significantly inhibited the activation of untransformed human T-cells derived from healthy donors or RA patients, and downregulated the expression of the transcription factor RORγt, and the TH17-related cytokines IL-17A, IL-17F, and IL-22, which play a major role within the pathophysiology of many chronic inflammatory/autoimmune diseases. The inhibitory effects of SFN could be abolished by exogenously supplied GSH and by the GSH replenishing antioxidant N-acetylcysteine (NAC). Together, our study provides mechanistic insights into the mode of action of the natural substance SFN. It specifically exerts TH17 prone immunosuppressive effects on untransformed human T-cells by decreasing GSH and accumulation of ROS. Thus, SFN may offer novel clinical options for the treatment of TH17 related chronic inflammatory/autoimmune diseases such as rheumatoid arthritis.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.